Posts

Posted on

BigCommerce Launches Open Checkout, Bringing Open Source Innovation to Online Checkout Experiences

BigCommerce Launches Open Checkout, Bringing Open Source Innovation to Online Checkout Experiences

Company becomes the only leading SaaS ecommerce platform to make checkout source code publicly available for front-end customization

AUSTIN, Texas–(BUSINESS WIRE)–BigCommerce (Nasdaq: BIGC), a leading Open SaaS ecommerce platform for fast-growing and established brands, today launched Open Checkout, an open source extension of the platform’s native checkout built to empower merchants, developers and partners to design fully-customized checkout experiences. With the global rollout of Open Checkout, BigCommerce establishes itself as the only leading SaaS ecommerce platform to offer a production-level checkout with an open source front-end.

More than 88 percent of all digital shopping carts were abandoned by shoppers in March 2020, according to Statista.1 Open Checkout’s publicly available front-end source code puts brands in the driver’s seat by providing an unprecedented level of flexibility to define every pixel of their checkout page and build truly differentiated shopping experiences. Additionally, Open Checkout leverages the same production-level source code that powers the platform’s native checkout solution, and is actively maintained by BigCommerce’s global team of engineers, making it easy for developers to apply updates on-demand.

“Today’s unveiling of BigCommerce’s Open Checkout is an important milestone that advances BigCommerce’s Open SaaS strategy by leveraging the benefits of Open Source without compromising the speed, security and simplicity that can only be achieved through a SaaS solution,” said Jimmy Duvall, chief product officer at BigCommerce. “By opening up the presentation layer, brands of all sizes selling on BigCommerce can create unique experiences that resonate with shoppers and streamline their path to purchase.”

Developed in React, Open Checkout builds upon BigCommerce’s Checkout SDK and jump-starts development of bespoke features and use cases, such as:

  • Branded Checkout Pages: Design a cohesive brand experience throughout the customer journey by adding custom CSS rules and JavaScript applications
  • Modernized B2B Buying: Streamline B2B purchasing by inserting custom fields for buyers to enter account information, pay using purchase order, or submit an order without collecting payment at checkout
  • Adapt to New Retail Environments: Optimize checkout pages to facilitate modern delivery options including buy online, pick-up in store; schedule delivery dates; or facilitate pickup from shared locations like lockers and brick-and-mortar stores
  • Customer Group Rules: Present a unique front-end interface using customer group rules to offer specific pricing, payment and shipping methods directly on the checkout page

IntuitSolutions, an Elite BigCommerce Partner, is one of the first agencies to tap into Open Checkout to develop its Ebizio Checkout application, which includes six pre-built functionalities, including several of the aforementioned use cases.

“Throughout our partnership with BigCommerce, IntuitSolutions’ clients have greatly benefited from the custom applications we’ve been able to develop by building on top of an industry-leading checkout,” said Eric Hansen, chief marketing officer at IntuitSolutions.

“Open Checkout’s extensible architecture allowed our team to bring Ebizio Checkout to market faster than we had anticipated.”

Open Checkout’s front-end source code is publicly available now on GitHub, and experience-led brands interested in learning more about how BigCommerce can enable their business to build, innovate and grow can visit the BigCommerce Developer Blog for additional information.

1Online shopping cart abandonment rate in selected industries in March 2020. Statista. 2020.

About BigCommerce

BigCommerce (Nasdaq: BIGC) is a leading software-as-a-service (SaaS) ecommerce platform that empowers merchants of all sizes to build, innovate and grow their businesses online. As a leading open SaaS solution, BigCommerce provides merchants sophisticated enterprise-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2B and B2C companies across 150 countries and numerous industries use BigCommerce to create beautiful, engaging online stores, including Ben & Jerry’s, Molton Brown, S.C. Johnson, Skullcandy, Sony, Vodafone and Woolrich. Headquartered in Austin, BigCommerce has offices in San Francisco, Sydney and London. Learn more at www.bigcommerce.com.

BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners.

Rachael Hensley

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Online Retail Data Management Retail Other Retail Technology Software Internet

MEDIA:

Logo
Logo
Posted on

Rational Advisors Surpasses $1 Billion in Assets Under Management

Rational Advisors Surpasses $1 Billion in Assets Under Management

The alternative-focused fund company has 75% growth year-to-date

NEW YORK–(BUSINESS WIRE)–
Rational Advisors, an alternative-focused fund company, today announced that the company has surpassed $1 billion in assets under management (AUM). This represents a 75% growth in assets since the beginning of the year and more than a 325% growth in assets since Rational acquired Huntington Asset Advisors, Inc. on December 31, 2015.

“We are thrilled to have surpassed $1 billion in AUM in less than five years after closing on our acquisition of Huntington Asset Advisors,” commented Jerry Szilagyi, President of Rational Advisors, Inc. “We reached this milestone by refocusing the company on distinct, non-traditional investment products that enhance investor portfolios. We are committed to this tradition as Rational continues to grow.”

Rational Advisors manages a range of non-traditional investment strategies and products. The company currently offers eight mutual funds under the Rational Funds brand, two variable annuity (VA) funds under the Rational VA Funds brand and two ETFs under the Strategy Shares ETFs brand. Within the last two years, the company’s funds have received several prestigious industry awards, including Investors Choice awards, HFM awards, and a Refinitiv Lipper award.

For more information on Rational and its various products, please visit: www.rationalmf.com and www.strategysharesetfs.com or call (800) 253-0412.

About Rational Advisors

Rational Advisors currently manages 12 non-traditional strategies across three brands, including Rational Funds, Rational VA Funds and Strategy Shares ETFs. Rational offers these exclusive strategies through a team of in-house portfolio managers and boutique institutional investment management partners. The firm’s innovative strategies are designed to support financial advisors and their clients in meeting the challenges of an ever-changing global financial market. The company is an innovative firm that strives for a culture of entrepreneurship and inclusion.

Investors should carefully consider the investment objectives, risks, charges and expenses of the Rational Funds and Strategy Shares ETFs. This and other important information about the Funds is contained in the prospectus, which can be obtained by calling (800) 253-0412 or at www.rationalmf.com and www.strategysharesetfs.com. The prospectus should be read carefully before investing. The Rational Funds are distributed by Northern Lights Distributors, LLC member FINRA/SIPC. Rational Advisors, Inc. is not affiliated with Northern Lights Distributors, LLC. Strategy Shares ETFs are distributed by Foreside Fund Services LLC. Rational Advisors, Inc. is not affiliated with Foreside Fund Services LLC. 9215-NLD-11/13/2020

Sarah Streeter

646-757-8063

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Posted on

More Regulations on the Horizon for Banks as Pandemic Exposes Security and Identity Verification Deficiencies

More Regulations on the Horizon for Banks as Pandemic Exposes Security and Identity Verification Deficiencies

OneSpan Global Financial Regulations Report reveals coming regulations on identity verification, Open Banking, AI, cryptocurrencies and biometric authentication aimed at enabling secure, digital economies

CHICAGO–(BUSINESS WIRE)–
OneSpan™ (NASDAQ: OSPN), the global leader in securing remote banking transactions, today released the inaugural OneSpan Global Financial Regulations Report. The report examines regulatory and legislative initiatives impacting financial services globally in fraud prevention, digital identity, data protection, payments, Open Banking, e-signatures and more.

Governments around the world are considering and enacting laws, policies and regulations to enable and protect digital transactions and commerce, with the global COVID-19 pandemic further increasing the focus on remote banking, telehealth and other remote alternatives for essential activities. This is in large part due to the pandemic having exposed shortcomings in the current security, data management and privacy policies of financial institutions and others. At the same time, the race to digitize the industry to keep pace with evolving customer expectations and competition is also driving rapid regulatory change.

As a result, there will likely be more data privacy and data protection laws enacted throughout the world, each bringing unique regulatory requirements for financial institutions. To help financial services leaders navigate the uncertainty, the OneSpanGlobal Financial Regulations Report includes guidance on the following trends:

  • Artificial Intelligence is under increasing scrutiny as adoption grows: Regulators and governments worldwide are grappling with the creation of frameworks for the development and application of AI that focus on data protection and privacy, as well as the ethical and transparent use of the data.
  • Digital identities and remote account openings are gaining traction worldwide: Regulators in Hong Kong, Pakistan, Greece, Macedonia, Mexico and Turkey approved remote bank account openings in 2020 – a clear indicator that even processes rooted in traditional face-to-face meetings in the branch are now going digital and touchless around the globe.
  • Open Banking is growing rapidly throughout the world: As third-party providers (TPPs) are allowed to use banking information to help consumers save money, borrow more easily and pay efficiently, banks will increasingly work with TPPs. In the U.S., the Consumer Financial Protection Board (CFPB) issued an Advanced Notice of Proposed Rulemaking on consumer authorized access to financial data, which could be the catalyst for Open Banking in America.
  • Facial recognition is driving the greatest changes to banking regulations: As banks increasingly use facial recognition technology for Identity Verification requirements, they are housing large amounts of consumer biometric data. Standards organizations such as the National Institute of Standards and Technology (NIST) and Fast IDentity Online (FIDO) Alliance are developing frameworks that could be adopted at the national level and would stipulate how banks protect and store their customers’ biometric data.
  • Regulation is on the way for cryptocurrencies: As digital banking platforms have experienced massive growth, many governments and industry bodies worldwide have begun to look to Central Bank Digital Currencies (CBDCs) and cryptocurrencies in terms of what they might add to the financial sector. This has resulted in new and refreshed conversations around the possible uses of CBDCs and cryptocurrencies.

“The COVID-19 pandemic has presented financial institutions with major economic and operational challenges and accelerated the need for digital transformation at the same time as the industry grapples with an increasingly complex global regulatory environment,” said OneSpan CEO, Scott Clements. “OneSpan’s inaugural Global Financial Regulations Report will arm banks and financial institutions with information they need to both be compliant and sustain their competitive position.”

Download a copy of the full report at www.onespan.com/resources/onespan-global-financial-regulations-report.

About OneSpan

OneSpan helps protect the world from digital fraud by establishing trust in people’s identities, the devices they use and the transactions they carry out. We do this by making digital banking accessible, secure, easy and valuable. OneSpan’s Trusted Identity platform and security solutions significantly reduce digital transaction fraud and enable regulatory compliance for more than 10,000 customers, including over half of the top 100 global banks. Whether through automating agreements, detecting fraud or securing financial transactions, OneSpan helps reduce costs and accelerate customer acquisition while improving the user experience. Learn more at OneSpan.com.

Copyright© 2020 OneSpan North America Inc., all rights reserved. OneSpan™ is a registered or unregistered trademarks of OneSpan North America Inc. or its affiliates in the U.S. and other countries. Any other trademarks cited herein are the property of their respective owners.

Media contacts:

Nicole Bosgraaf

Sr. Public Relations Manager

OneSpan

+1-401-219-2131

[email protected]

Sarah Hanel

Global Director of Corporate Communications

OneSpan

+1-312-871-1729

[email protected]

KEYWORDS: Illinois New York United States North America

INDUSTRY KEYWORDS: Data Management Technology Other Retail Mobile/Wireless Retail Other Communications Other Professional Services Small Business Finance Communications Security Banking Professional Services Other Technology Social Media Telecommunications Software Networks Internet Online Retail

MEDIA:

Posted on

Arrow Electronics to Present at Upcoming Virtual Investor Conferences

Arrow Electronics to Present at Upcoming Virtual Investor Conferences

CENTENNIAL, Colo.–(BUSINESS WIRE)–
Arrow Electronics, Inc. (NYSE:ARW) announced that Chris Stansbury, senior vice president and chief financial officer, will present at the 2020 Wells Fargo TMT Summit on Dec. 1, 2020 at 10:40 A.M. Eastern Time. Mr. Stansbury will also present at the Raymond James 2020 Technology Investors Conference on Dec. 7, 2020 at 2:20 P.M. Eastern Time.

The presentations will be available via live webcasts. To access the webcasts visit investor.arrow.com, where additional investor information is also available. The webcasts will remain available for two weeks following the presentation dates.

Arrow Electronics guides innovation forward for over 175,000 leading technology manufacturers and service providers. With 2019 sales of $29 billion, Arrow develops technology solutions that improve business and daily life. Learn more at fiveyearsout.com.

Steven O’Brien

Vice President, Investor Relations

303-824-4544

Media Contact:

John Hourigan

Vice President, Global Communications

303-824-4586

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Technology Semiconductor Security Telecommunications Software Networks Hardware Data Management Consumer Electronics VoIP

MEDIA:

Logo
Logo
Posted on

NantHealth and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

NantHealth and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Study demonstrates the viability and value of RNA sequencing from formalin fixed samples in gaining a deeper understanding of patient disease biology and in delivering diagnostic, prognostic, and therapeutic value in a clinical setting

RNA sequencing provides the potential to molecularly define a patient’s cancer, identify its origin, and, most importantly, optimize treatment plans for the highest chance of success, especially with immunotherapies

CULVER CITY, Calif. & EL SEGUNDO, Calif.–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the publication of a study that revealed RNA sequencing is not only viable but may also provide significant clinical value in analyzing a cancer patient’s specific disease biology to enable an optimized treatment decision with a higher likelihood of success. The study was published in Nature’s Scientific Reports, an open access, peer-reviewed journal dedicated to original research from across all areas of the natural and clinical sciences.

Prepared in collaboration with NantOmics, LLC and ImmunityBio, Inc., the study was designed to explore the potential use of formalin-fixed paraffin-embedded (FFPE)-derived RNA transcriptome profiling for clinical decision-making. This technique was previously not considered to yield significant clinical value due to the lower quality, degraded samples typically produced by the formalin fixation process. FFPE is the most common method used in clinical settings for storing tumor biopsies.

The study revealed an overall sequencing success rate of 81% with highly consistent coverage in direct FFPE and fresh-frozen (FF) replicates (98% agreement). The results provide strong rationale for the use of FFPE-derived RNA sequencing in clinical decision-making based on the reproducibility, robustness, and consistency of whole transcriptome profiling. This research enables the comparison of clinical samples to research studies, which generally differ in both data collection and sequencing methods, and which may unlock highly valuable insights that would not be possible with DNA sequencing techniques alone.

“This is an important step to advancing towards molecularly informed medicine, both from the perspective of diagnostics to precise therapeutic intervention,” said Dr. Patrick Soon-Shiong, CEO of NantHealth, NantOmics and ImmunityBio. “Genomic reporting capabilities could be enhanced through clinical applications resulting from this technology, including identifying cancers of unknown primary (CUP), prevalence of immune cell infiltrates in the tumor microenvironment (immunome), and expression analysis of checkpoint markers including those targeted by commercial and investigational immunotherapies,” he continued.

The study also demonstrates that RNA sequencing is not only clinically viable but valuable and can provide a more thorough understanding of what genes are driving each individual patient’s tumor to better inform personalized treatment decisions.

To achieve this, researchers performed ribo-deplete RNA extractions on more than 3,200 FFPE slide samples to measure the expression of clinically significant genes that help identify treatments with the highest likelihood of response. The study included a comprehensive evaluation of RNA extraction methods (Poly-A and ribo-depletion) by comparing transcriptomes from The Cancer Genome Atlas (TCGA) cohort and 3,116 FFPE samples. Findings showed minimal differences between the two approaches within clinically important genes, while establishing a computational framework for comparing the expression of FFPE clinical samples to the growing database of research samples generated by academic studies.

“These are very exciting results from a robust scientific study of a high caliber,” said Shahrooz Rabizadeh, Ph.D., Chief Scientific Officer, ImmunityBio. “The implication of using RNA sequencing to molecularly define a patient’s cancer, identify the origin of cancers of unknown primary, and most importantly, optimize treatment plans for the highest chance of success, especially with immunotherapies, is profound.”

“Through this research, we demonstrated the robustness of the RNA assay and the informatics techniques that help clinicians understand the transcriptional drivers of disease in their patients, allowing the further advancement of personalized medicine,” said Dr. Sandeep “Bobby” Reddy, Chief Medical Officer, NantHealth. “NantHealth knows that high-quality data is the backbone of modern medicine. This study unlocks valuable insights through a method that allows the analysis of both academic research and clinical data for treatment optimization, further strengthening our fight against cancer.”

Receiving widespread attention in policy documents and the media, Scientific Reports is the seventh most-cited journal in the world, with more than 350,000 citations. The publication has an extensive network of expert peer reviewers and an editorial team who provide rigorous and objective review. Scientific Reports is guided by the same ethical and editorial guidelines as other Nature Research publications to ensure that all the research is original, scientifically robust and of the highest quality. The journal is published through a number of different channels, including nature.com, where it receives approximately two million monthly visitors.

About NantHealth, Inc.

NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret, and visualize complex and highly sensitive information, NantHealth helps its customers in healthcare, life sciences, logistics, telecommunications, and other industries, to automate, understand, and act on data while keeping it secure and scalable. NantHealth’s product portfolio comprises the latest technology in molecular analysis (GPS Cancer), payer/provider collaboration platforms for real-time coverage decision support (NaviNet and Eviti), and Data Products that provide multi-data analysis, reporting and professional services offerings. OpenNMS, a NantHealth subsidiary, helps businesses monitor and manage network health and performance. For more information, visit nanthealth.com, follow us on Twitter, Facebook and LinkedIn, and subscribe to our blog.

Forward Looking Statement

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to integrate OpenNMS into our operations;; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

About ImmunityBio

ImmunityBio, Inc. is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.” This novel approach is designed to eliminate the need for high-dose chemotherapy, improve upon the outcomes of current CAR T-cell therapies, and extend beyond checkpoint inhibitors.

ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.

Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). The company is also in Phase 2 or 3 trials for indications such as first- and second-line lung cancer, triple-negative breast cancer, metastatic pancreatic cancer, recurrent glioblastoma, and soft tissue sarcoma in combination with the company’s synthetic immune modulator (aldoxorubicin).

ImmunityBio is also developing therapies, including vaccines, for the prevention and treatment of HIV, influenza, and the coronavirus SARS-CoV-2 with its second-generation human adenovirus (hAd5) vaccine technologies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that ImmunityBio will be successful in improving the treatment of various diseases, including, but not limited to the novel coronavirus and cancer. Risks and uncertainties related to this endeavor include, but are not limited to, the company’s beliefs regarding the success, cost, and timing of its development activities and clinical trials.

Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

Jen Hodson

NANT

[email protected]

562-397-3639

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Science Software Biotechnology Research Oncology Health Technology Genetics

MEDIA:

Logo
Logo
Posted on

Eagle Point Income Company Inc. Announces Third Quarter 2020 Financial Results

Eagle Point Income Company Inc. Announces Third Quarter 2020 Financial Results

GREENWICH, Conn.–(BUSINESS WIRE)–
Eagle Point Income Company Inc. (the “Company”) (NYSE: EIC) today announced financial results for the quarter ended September 30, 2020, net asset value (“NAV”) as of September 30, 2020 and certain additional activity through October 31, 2020.

THIRD QUARTER 2020 HIGHLIGHTS

  • Net investment income (“NII”) of $0.28 per weighted average common share.1
  • NAV per common share of $14.84 as of September 30, 2020.
  • Third quarter 2020 GAAP net income (inclusive of unrealized mark-to-market gains) of $6.9 million, or $1.13 per weighted average common share.
  • Weighted average effective yield of the Company’s collateralized loan obligation (“CLO”) debt and equity portfolio (based on amortized cost) was 8.84% as of September 30, 2020.
  • Deployed $3.6 million in gross capital in the third quarter of 2020.

SUBSEQUENT EVENTS

  • NAV per common share estimated to be between $14.66 and $14.70 as of October 31, 2020.
  • All investments in the Company’s portfolio that were scheduled to make distributions in October did so.
  • As of October 31, 2020, the Company had approximately $19.3 million of cash and capacity on its revolving credit facility available for investment.

“We are very pleased with the Company’s third quarter performance. The Company generated net investment income of $0.28 per share, which is above our distribution level, and our portfolio’s value continued to increase,” said Thomas Majewski, Chairman and Chief Executive Officer. “All of the investments in our portfolio that were scheduled to make payments in October did so. As the benefit of LIBOR floors became more pronounced in our CLO equity portfolio, total portfolio collections in October exceeded our July tally.”

THIRD QUARTER 2020 RESULTS

The Company’s NII for the quarter ended September 30, 2020 was $0.28 per weighted average common share. The Company had no meaningful realized gains or losses during the quarter. This compared to $0.34 of NII and realized gains per weighted average common share for the quarter ended June 30, 2020.

For the quarter ended September 30, 2020, the Company recorded GAAP net income of $6.9 million, or $1.13 per weighted average common share. The net gain was comprised of total investment income of $2.5 million and net unrealized appreciation on investments of $5.2 million, partially offset by total expenses of $0.8 million and de minimis net realized loss on investments.

NAV as of September 30, 2020 was $90.6 million, or $14.84 per common share, which is $0.70 per common share higher than the Company’s NAV as of June 30, 2020.

During the quarter ended September 30, 2020, the Company deployed $3.6 million in gross capital.

As of September 30, 2020, the weighted average effective yield on the Company’s CLO debt and equity portfolio (based on amortized cost) was 8.84%.

PORTFOLIO STATUS

As of September 30, 2020, on a look-through basis, and based on the most recent CLO trustee reports received by such date, the Company had indirect exposure to approximately 1,255 unique corporate obligors. The largest look-through obligor represented 1.4% of the Company’s CLO debt and equity portfolio. The top-ten largest look-through obligors together represented 6.4% of the Company’s CLO debt and equity portfolio.

As of September 30, 2020, the Company had $12.0 million in outstanding borrowings from the revolving credit facility, representing leverage of 11.7% of total assets (less current liabilities).Over the long term, management expects the Company to operate under normal market conditions generally with leverage of approximately 20% of total assets. Based on applicable market conditions at any given time, or should significant opportunities present themselves, the Company may incur leverage in excess of this amount, subject to applicable regulatory limits.

FOURTH QUARTER 2020 PORTFOLIO ACTIVITY THROUGH OCTOBER 31, 2020 AND OTHER UPDATES

As of October 31, 2020, the Company had approximately $19.3 million of cash and capacity on its revolving credit facility available for investment.

As previously published on the Company’s website, management’s estimate of the Company’s range of NAV per common share as of October 31, 2020 was $14.66 to $14.70.

DISTRIBUTIONS

The Company paid a monthly distribution of $0.08 per common share on October 30, 2020 to stockholders of record as of October 13, 2020. Additionally, and as previously announced, the Company declared distributions of $0.08 per share of common stock payable on November 30, 2020, December 31, 2020, January 29, 2021, February 26, 2021 and March 31, 2021 to stockholders of record as of November 12, 2020, December 11, 2020, January 12, 2021, February 12, 2021 and March 12, 2021, respectively. The ability of the Company to declare and pay distributions is subject to several factors, including the Company’s results of operations.

SPECIAL DISTRIBUTIONS

As one of the requirements for the Company to maintain its ability to be taxed as a “regulated investment company” (which it has elected to be), the Company is generally required to pay distributions to holders of its common stock in an amount equal to substantially all of the Company’s taxable income.

As previously announced, the Company determined that its taxable income for the tax year ended December 31, 2019 exceeded the aggregate amount of distributions paid to common stockholders during 2019 and, as a result, the Company declared two special distributions of $0.19 per common share. The Company paid the first special distribution of $0.19 per common share on July 31, 2020 to stockholders of record as of July 13, 2020. The Company paid the second special distribution of $0.19 per common share on October 30, 2020 to stockholders of record on October 13, 2020.

CONFERENCE CALL

The Company will host a conference call at 11:30 a.m. (Eastern Time) today to discuss the Company’s financial results for the quarter ended September 30, 2020, as well as a portfolio update.

All interested parties may participate in the conference call by dialing (877) 407-0789 (domestic) or (201) 689-8562 (international). Please reference Conference ID 13712475 when calling and you are invited to dial in approximately 10 to 15 minutes prior to the start of the call.

A live webcast will also be available on the Company’s website (www.eaglepointincome.com). Please go to the Investor Relations section at least 15 minutes prior to the call to register, download and install any necessary audio software.

An archived replay of the call will be available shortly afterwards until December 17, 2020. To hear the replay, please dial (844) 512-2921 (toll-free) or (412) 317-6671 (international). For the replay, enter Conference ID 13712475.

ADDITIONAL INFORMATION

The Company has made available on the investor relations section of its website, www.eaglepointincome.com (in the financial statements and reports section), its unaudited financial statements as of and for the period ended September 30, 2020. The Company has also filed this report with the Securities and Exchange Commission (“SEC”). The Company also published on its website (in the presentations and events section) an investor presentation, which contains additional information about the Company and its portfolio as of and for the quarter ended September 30, 2020.

ABOUT EAGLE POINT INCOME COMPANY

The Company is a non-diversified, closed-end management investment company. The Company’s primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation, by investing primarily in junior debt tranches of CLOs. In addition, the Company may invest up to 20% of its total assets (at the time of investment) in CLO equity securities and related securities and instruments.

The Company makes certain unaudited portfolio information available each month on its website in addition to making certain other unaudited financial information available on its website (www.eaglepointincome.com). This information includes (1) an estimated range of the Company’s net investment income (“NII”) and realized gains or losses per share of common stock for each calendar quarter end, generally made available within the first fifteen days after the applicable calendar month end, (2) an estimated range of the Company’s net asset value (“NAV”) per share of common stock for the prior month end and certain additional portfolio-level information, generally made available within the first fifteen days after the applicable calendar month end, and (3) during the latter part of each month, an updated estimate of NAV, if applicable, and, with respect to each calendar quarter end, an updated estimate of the Company’s NII and realized gains or losses per share for the applicable quarter, if available.

FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company’s other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

1 “Per weighted average common share” data are on a weighted average basis based on the average daily number of shares of common stock outstanding for the period and “per common share” refers to per share of the Company’s common stock.

Investor and Media Relations:

ICR

203-340-8510

[email protected]

www.eaglepointincome.com

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Eagle Point Credit Company Inc. Announces Third Quarter 2020 Financial Results

Eagle Point Credit Company Inc. Announces Third Quarter 2020 Financial Results

GREENWICH, Conn.–(BUSINESS WIRE)–
Eagle Point Credit Company Inc. (the “Company”) (NYSE: ECC, ECCB, ECCX, ECCY) today announced financial results for the quarter ended September 30, 2020, net asset value (“NAV”) as of September 30, 2020 and certain additional activity through October 31, 2020.

THIRD QUARTER HIGHLIGHTS

  • Net investment income (“NII”) and realized losses of $0.23 per weighted average common share1 for the third quarter of 2020.
  • NAV per common share of $8.45 as of September 30, 2020.
  • Third quarter 2020 GAAP net income (inclusive of unrealized mark-to-market gains) of $44.5 million, or $1.40 per weighted average common share.
  • Weighted average effective yield of the Company’s collateralized loan obligation (“CLO”) equity portfolio (excluding called CLOs) was 11.48% as of September 30, 2020. Weighted average expected yield of the Company’s CLO equity portfolio (excluding called CLOs), based on fair market value, was 27.81% as of September 30, 20202.
  • Deployed $27.2 million in net capital and received $16.7 million in recurring cash distributions3 from the Company’s investment portfolio in the third quarter of 2020. Including proceeds from called investments, the Company received cash distributions of $19.7 million over the same period.

SUBSEQUENT EVENTS

  • NAV per common share estimated to be between $8.53 and $8.63 as of October 31, 2020.
  • Received $25.5 million of recurring cash distributions from the Company’s investment portfolio during October 2020, an increase of over 50% from the third quarter.
  • Deployed $6.9 million in net capital during October 2020.

“We saw our investment portfolio’s value continue to rebound in the third quarter, with our NAV increasing 13% from the end of the second quarter,” said Thomas Majewski, Chief Executive Officer. “Our NII was $0.29 per share, above our current distribution rate, though we did also realize a few losses.”

“As we moved into October, recurring cash flows on our portfolio increased by over 50% as LIBOR mismatches from the second and third quarter turned in the Company’s favor,” added Mr. Majewski. “Our overall liquidity position remains strong, with no maturities prior to October 2026 and over $12 million of cash on our balance sheet at the end of October.”

THIRD QUARTER 2020 RESULTS

The Company’s NII and realized losses for the quarter ended September 30, 2020 was $0.23 per weighted average common share. This compared to $0.28 of NII and realized losses per weighted average common share for the quarter ended June 30, 2020, and $0.37 of NII and realized gains per weighted average common share for the quarter ended September 30, 2019.

For the quarter ended September 30, 2020, the Company recorded GAAP net income of $44.5 million, or $1.40 per weighted average common share. Net income was comprised of total investment income of $16.0 million and total net unrealized appreciation (or unrealized mark-to-market gains in the value of the Company’s investments and certain liabilities at fair value) of $37.3 million, partially offset by expenses of $7.0 million and realized losses of $1.8 million.

NAV as of September 30, 2020 was $268.2 million, or $8.45 per common share, which is $1.00 per common share higher than the Company’s NAV as of June 30, 2020, and $3.00 per common share lower than the Company’s NAV as of September 30, 2019.

During the quarter ended September 30, 2020, the Company deployed $27.2 million in net capital, and converted 3 of its existing loan accumulation facilities into CLOs. The weighted average effective yield of new CLO equity investments made by the Company during the quarter, which includes a provision for credit losses, was 15.22% as measured at the time of investment.

During the quarter ended September 30, 2020, the Company received $16.7 million of recurring cash distributions from its investment portfolio, or $0.53 per weighted average common share, which was in excess of the Company’s aggregate distributions on its common stock and recurring operating costs for the quarter. When including proceeds from called investments, the Company received cash distributions of $0.62 per weighted average common share during the quarter.

As of September 30, 2020, based on amortized cost, the weighted average effective yield on the Company’s CLO equity portfolio (excluding called CLOs) was 11.48%, compared to 12.33% as of June 30, 2020 and 13.38% as of September 30, 2019.

Pursuant to the Company’s “at-the-market” offering program, the Company issued 81,581 shares of common stock at a premium to NAV during the third quarter for total net proceeds to the Company of approximately $0.6 million.

PORTFOLIO STATUS

As of September 30, 2020, on a look-through basis, and based on the most recent CLO trustee reports received by such date, the Company had indirect exposure to approximately 1,484 unique corporate obligors. The largest look-through obligor represented 1.0% of the Company’s CLO equity and loan accumulation facility portfolio. The top-ten largest look-through obligors together represented 5.9% of the Company’s CLO equity and loan accumulation facility portfolio.

The look-through weighted average spread of the loans underlying the Company’s CLO equity and related investments was 3.59% as of September 2020, up from 3.55% as of June 2020.

As of September 30, 2020, the Company had debt and preferred securities outstanding which totaled approximately 34.7% of its total assets (less current liabilities). Over the long-term, management expects to operate the Company generally with leverage within a range of 25% to 35% of total assets under normal market conditions. Based on applicable market conditions at any given time, or should significant opportunities present themselves, the Company may incur leverage outside of this range, subject to applicable regulatory limits.

FOURTH QUARTER 2020 PORTFOLIO ACTIVITY THROUGH OCTOBER 31, 2020 AND OTHER UPDATES

From October 1, 2020 through October 31, 2020, the Company received $25.5 million of recurring cash distributions from its investment portfolio. As of October 31, 2020, some of the Company’s investments had not yet reached their payment date for the quarter. Also, from October 1, 2020 through October 31, 2020, the Company deployed $6.9 million in net capital.

As of October 31, 2020, the Company had approximately $12.9 million of cash available for investment.

As previously published on the Company’s website, management’s estimate of the Company’s range of NAV per common share as of October 31, 2020 was $8.53 to $8.63.

DISTRIBUTIONS

The Company paid a monthly distribution of $0.08 per common share on October 30, 2020 to stockholders of record as of October 13, 2020. Additionally, and as previously announced, the Company declared distributions of $0.08 per share of common stock payable on November 30, 2020, December 31, 2020, January 29, 2021, February 26, 2021 and March 31, 2021 to stockholders of record as of November 12, 2020, December 11, 2020, January 12, 2021, February 12, 2021 and March 12, 2021, respectively. The ability of the Company to declare and pay distributions is subject to a number of factors, including the Company’s results of operations.

The Company paid a monthly distribution of $0.161459 per share of the Company’s Series B Term Preferred Stock due 2026 (NYSE: ECCB) on October 31, 2020, to stockholders of record as of October 13, 2020. The distribution represented a 7.75% annualized rate, based on the $25 liquidation preference per share for the Series B Term Preferred Stock. Additionally, and as previously announced, the Company declared distributions of $0.161459 per share on Series B Term Preferred Stock, payable on each of November 30, 2020, December 31, 2020, January 29, 2021, February 26, 2021 and March 31, 2021 to stockholders of record as of November 12, 2020, December 11, 2020, January 12, 2021, February 12, 2021 and March 12, 2021, respectively.

CONFERENCE CALL

The Company will host a conference call at 10:00 a.m. (Eastern Time) today to discuss the Company’s financial results for the quarter ended September 30, 2020, as well as a portfolio update.

All interested parties may participate in the conference call by dialing (877) 407-0789 (toll-free) or (201) 689-8562 (international), and referencing Conference ID 13712484 approximately 10 to 15 minutes prior to the call.

A live webcast will also be available on the Company’s website (www.eaglepointcreditcompany.com). Please go to the Investor Relations section at least 15 minutes prior to the call to register, download and install any necessary audio software.

An archived replay of the call will be available shortly afterwards until December 17, 2020. To hear the replay, please dial (844) 512-2921 (toll-free) or (412) 317-6671 (international). For the replay, enter Conference ID 13712484.

ADDITIONAL INFORMATION

The Company has made available on the investor relations section of its website, www.eaglepointcreditcompany.com (in the financial statements and reports section), its unaudited consolidated financial statements as of and for the period ended September 30, 2020. The Company has also filed this report with the Securities and Exchange Commission. The Company also published on its website (in the presentations and events section) an investor presentation, which contains additional information about the Company and its portfolio as of and for the quarter ended September 30, 2020.

ABOUT EAGLE POINT CREDIT COMPANY

The Company is a non-diversified, closed-end management investment company. The Company’s primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation, primarily through investment in equity and junior debt tranches of collateralized loan obligations. The Company is externally managed and advised by Eagle Point Credit Management LLC.

The Company makes certain unaudited portfolio information available each month on its website in addition to making certain other unaudited financial information available on its website (www.eaglepointcreditcompany.com). This information includes (1) an estimated range of the Company’s net investment income (“NII”) and realized gains or losses per share of common stock for each calendar quarter end, generally made available within the first fifteen days after the applicable calendar month end, (2) an estimated range of the Company’s net asset value (“NAV”) per share of common stock for the prior month end and certain additional portfolio-level information, generally made available within the first fifteen days after the applicable calendar month end, and (3) during the latter part of each month, an updated estimate of NAV, if applicable, and, with respect to each calendar quarter end, an updated estimate of the Company’s NII and realized gains or losses per share for the applicable quarter, if available.

FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”). The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

1 “Per weighted average common share” data are on a weighted average basis based on the average daily number of shares of common stock outstanding for the period and “per common share” refers to per share of the Company’s common stock.

2 Weighted average effective yield is based on an investment’s amortized cost whereas weighted average expected yield is based on an investment’s fair market value as of the applicable period end as disclosed in the Company’s financial statements, which is subject to change from period to period. Please refer to the Company’s quarterly unaudited financial statements for additional disclosures.

3 “Recurring cash distributions” refers to the quarterly distributions received by the Company from its CLO equity and debt investments and distributions from loan accumulation facilities in excess of capital invested and excludes funds received from CLOs called.

Investor and Media Relations:

ICR

203-340-8510

[email protected]

www.eaglepointcreditcompany.com

KEYWORDS: Connecticut United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Posted on

Lightlife® Strengthens Walmart Partnership by Expanding Tempeh to 3,500 Stores to Meet Growing Demand for Plant-Based Protein

Lightlife® Strengthens Walmart Partnership by Expanding Tempeh to 3,500 Stores to Meet Growing Demand for Plant-Based Protein

Leading Plant-Based Brand’s Tempeh line now available at more than 18,500 retail stores nationwide

CHICAGO–(BUSINESS WIRE)–
Greenleaf Foods, SPC today announced a significant retail expansion of its Lightlife® (“Lightlife”) brand Tempeh—a versatile, high-protein, naturally-fermented food that appeals to plant-based and meat eaters alike. Lightlife Tempeh is now available in more than 3,500 Walmart locations nationwide—a more than ten-fold growth from its previous 300 stores—bringing the product’s retail distribution to over 18,500 retail locations. Lightlife is the market leader in tempeh, having grown at a rate of 44% in 2020 alone.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005277/en/

Lightlife Tempeh is organic, non-GMO, Kosher-certified and offers between 12 and 19 grams of protein per serving. Tempeh products can be eaten raw or cooked, crumbled onto salads, cubed or chopped into stir fry, and even sandwiched between warm bread. (Photo: Business Wire)

Lightlife Tempeh is organic, non-GMO, Kosher-certified and offers between 12 and 19 grams of protein per serving. Tempeh products can be eaten raw or cooked, crumbled onto salads, cubed or chopped into stir fry, and even sandwiched between warm bread. (Photo: Business Wire)

“Lightlife Tempeh accounted for about 80% of total U.S. tempeh dollar sales so far this year,”2 said Dan Curtin, president of Greenleaf Foods, SPC. “We are excited to grow our partnership with Walmart, the world’s largest retailer, and get tempeh into the hands of all consumers. This is only the beginning as we further grow the plant-based category with our variety of plant-based products.”3

Lightlife Original Tempeh is organic, non-GMO and made with just three simple ingredients: cultured organic soybeans, water and organic brown rice, all which are natural, nourishing ingredients that together serve as an excellent source of complete protein.

In addition to its Original Tempeh, other Lightlife Tempeh varieties include Buffalo Tempeh Strips, Smoky Tempeh Strips, Three Grain Tempeh and Flax Tempeh. All are organic, non-GMO, Kosher-certified and offer between 12 and 19 grams of protein per serving. Tempeh products can be eaten raw or cooked, crumbled onto salads, cubed or chopped into stir fry, and even sandwiched between warm bread.

Lightlife Original Tempeh is available now in the produce section at Walmart stores across the country, as well as Meijer, Publix, Kroger, Whole Foods and more.

Earlier this year, Lightlife debuted a full brand refresh, making the logo more balanced and approachable, with a spark of inspiration. Now consumers can expect to see newly-stocked Lightlife Tempeh products to reflect the bright and bold packaging design that’s rolling out into stores across the country over the next few weeks, as well.

For more information on Lightlife and for delicious recipe ideas, visit https://lightlife.com and follow @LightlifeFoods on Facebook, Instagram and YouTube.

About Greenleaf Foods, SPC

Greenleaf Foods, SPC, is transforming plant-based protein with a wide array of delicious and innovative products that satisfy consumers interested in adding protein variety to their diets. Our leading brands include Lightlife® (“Lightlife”) and Field Roast Grain Meat Co.™ (“Field Roast”). Together, these brands are delighting loyal, longtime fans and enticing new ones who never knew plant-based protein could taste so good. The Lightlife and Field Roast portfolios feature nearly 50 products and represent a leading market position in the refrigerated, plant-based protein category in the U.S. Greenleaf Foods, SPC is a wholly owned, independent subsidiary of Maple Leaf Foods Inc. (TSX:MFI).

1 SATORI, SPINS, Total MULO + Natural Channel, Latest 52 Weeks Ending 10/4/20.

2 SATORI, SPINS, Total MULO + Natural Channel, Latest 52 Weeks Ending 10/4/20.

3https://nrf.com/resources/top-retailers/top-100-retailers/top-100-retailers-2020-list

Nicole Pierce, Edible, 312 240 2729 or [email protected]

KEYWORDS: Illinois United States North America Canada

INDUSTRY KEYWORDS: Agriculture Natural Resources Specialty Food/Beverage Online Retail Consumer Other Consumer Retail

MEDIA:

Logo
Logo
Photo
Photo
Lightlife Tempeh is organic, non-GMO, Kosher-certified and offers between 12 and 19 grams of protein per serving. Tempeh products can be eaten raw or cooked, crumbled onto salads, cubed or chopped into stir fry, and even sandwiched between warm bread. (Photo: Business Wire)
Posted on

Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing. Dr. White brings over 20 years of experience overseeing the complexities of the chemistry manufacturing and controls process.

“Nicole will be a tremendous asset to Assembly Bio as we continue to progress our clinical development efforts, and we are thrilled to welcome her to the company,” said John McHutchison, AO, MD, Chief Executive Officer and President. “She is an established leader with proven success guiding programs throughout the entirety of the clinical lifecycle and ultimately to production of the commercial supply. Nicole will play a key strategic role in the advancement of our pipeline of core inhibitors, including vebicorvir, which we are preparing for Phase 3 studies next year.”

“I am excited to join the leadership team at Assembly Bio and to work alongside this group of world-class experts in virology,” said Dr. White. “The potential for core inhibitors to improve outcomes for people with HBV is something that I have followed with great interest, and I am eager to apply my experience and strong technical background to support the company’s commitment to bring new and long overdue treatment options to patients with chronic HBV.”

Prior to joining Assembly Bio, Dr. White headed Process Chemistry at Gossamer Bio and led chemistry, manufacturing and controls (CMC) for multiple early- and late-stage programs in development. Prior to that she held progressive leadership roles at Gilead Sciences to advance multiple programs from Phase 1 through commercial launch and helped guide the drug substance manufacturing and global outsourcing strategy. While at Gilead, Dr. White contributed to the development and commercial launch of multiple antiviral programs including Harvoni®, Vemlidy® and Vosevi®. She obtained a PhD in Organic Chemistry from the University of California, Irvine and a BS in Chemistry from the University of California, San Diego.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Forward-Looking Statements

The information in this press release contains forward-looking statements regarding future events, including statements about the therapeutic potential of our HBV product candidates. Certain forward-looking statements may be identified by reference to a future period or by use of forward-looking terminology such as “will,” “advance,” and “progress.” Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor
Contact

Assembly Biosciences, Inc.
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
[email protected]

Media Contact

Sam Brown Inc.
Audra Friis
(917) 519-9577
[email protected]



Posted on

Zscaler to Present at Upcoming Investor Conferences

SAN JOSE, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced that management is scheduled to present at upcoming investor conferences. Details for each event are as follows:

Credit Suisse Technology Conference
Thursday, December 3, 2020 at 10:30 a.m. PST (1:30 p.m. EST)

UBS Global TMT Conference
Monday, December 7, 2020 at 11:50 a.m. PST (2:50 p.m. EST)

Barclays Global Technology, Media and Telecommunications Conference
Thursday, December 10, 2020 at 10:00 a.m. PST (1:00 p.m. EST)

A live and archived audio webcast of each presentation will be available on the Investor Relations section of the Zscaler website at https://ir.zscaler.com/.

About Zscaler

Zscaler (NASDAQ: ZS) accelerates digital transformation so customers can be more agile, efficient, resilient, and secure. The Zscaler Zero Trust Exchange protects thousands of customers from cyberattacks and data loss by securely connecting users, devices, and applications in any location. Distributed across more than 150 data centers globally, the SASE-based Zero Trust Exchange is the world’s largest in-line cloud security platform.

Zscaler™, Zscaler Zero Trust Exchange™, Zscaler Internet Access™, and Zscaler Private Access™, ZIA™, and ZPA™ and Zscaler B2B™ are either (i) registered trademarks or service marks or (ii) trademarks or service marks of Zscaler, Inc. in the United States and/or other countries. Any other trademarks are the properties of their respective owners.

Media Contact:

Tom Stilwell
[email protected]

Investor Relations Contact:

Bill Choi, CFA
[email protected]